Cargando…
Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy
A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are based on total cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and most inter...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751280/ https://www.ncbi.nlm.nih.gov/pubmed/23888382 http://dx.doi.org/10.1007/s11886-013-0397-8 |
_version_ | 1782281567038603264 |
---|---|
author | Wiklund, Olov Pirazzi, Carlo Romeo, Stefano |
author_facet | Wiklund, Olov Pirazzi, Carlo Romeo, Stefano |
author_sort | Wiklund, Olov |
collection | PubMed |
description | A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are based on total cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and most intervention trials have targeted the LDL-C levels. Emerging measures, which in some cases may be better for risk calculation and as alternative treatment targets, are apolipoprotein B and non-HDL-C. Other lipid measures that may contribute in risk analysis are triglycerides (TG), lipoprotein(a), and lipoprotein-associated phospholipase A(2). The primary treatment target in cardiovascular prevention is LDL-C, and potential alternative targets are apoB and non-HDL-C. In selected individuals at high cardiovascular (CV) risk, TG should be targeted, but HDL-C, Lp(a), and ratios such as LDL-C/HDL-C or apoB/apoAI are not recommended as treatment targets. Lipids should be monitored during titration to targets. Thereafter, lipids should be checked at least once a year or more frequently to improve treatment adherence if indicated. Monitoring of muscle and liver enzymes should be done before the start of treatment. In stable conditions during treatment, the focus should be on clinical symptoms that may alert muscle or liver complications. Routine measurement of CK or ALT is not necessary during treatment with statins. |
format | Online Article Text |
id | pubmed-3751280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-37512802013-08-27 Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy Wiklund, Olov Pirazzi, Carlo Romeo, Stefano Curr Cardiol Rep Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor) A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are based on total cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and most intervention trials have targeted the LDL-C levels. Emerging measures, which in some cases may be better for risk calculation and as alternative treatment targets, are apolipoprotein B and non-HDL-C. Other lipid measures that may contribute in risk analysis are triglycerides (TG), lipoprotein(a), and lipoprotein-associated phospholipase A(2). The primary treatment target in cardiovascular prevention is LDL-C, and potential alternative targets are apoB and non-HDL-C. In selected individuals at high cardiovascular (CV) risk, TG should be targeted, but HDL-C, Lp(a), and ratios such as LDL-C/HDL-C or apoB/apoAI are not recommended as treatment targets. Lipids should be monitored during titration to targets. Thereafter, lipids should be checked at least once a year or more frequently to improve treatment adherence if indicated. Monitoring of muscle and liver enzymes should be done before the start of treatment. In stable conditions during treatment, the focus should be on clinical symptoms that may alert muscle or liver complications. Routine measurement of CK or ALT is not necessary during treatment with statins. Springer US 2013-07-26 2013 /pmc/articles/PMC3751280/ /pubmed/23888382 http://dx.doi.org/10.1007/s11886-013-0397-8 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor) Wiklund, Olov Pirazzi, Carlo Romeo, Stefano Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy |
title | Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy |
title_full | Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy |
title_fullStr | Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy |
title_full_unstemmed | Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy |
title_short | Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy |
title_sort | monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy |
topic | Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751280/ https://www.ncbi.nlm.nih.gov/pubmed/23888382 http://dx.doi.org/10.1007/s11886-013-0397-8 |
work_keys_str_mv | AT wiklundolov monitoringoflipidsenzymesandcreatinekinaseinpatientsonlipidloweringdrugtherapy AT pirazzicarlo monitoringoflipidsenzymesandcreatinekinaseinpatientsonlipidloweringdrugtherapy AT romeostefano monitoringoflipidsenzymesandcreatinekinaseinpatientsonlipidloweringdrugtherapy |